Rezolute Inc (RZLT)

$7.00 +0.04 (0.57%)
Market Cap 605.49M
Revenue (ttm) 0.00
Net Income (ttm) -68.46M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,131,100
Avg Vol 1,072,574
Day's Range N/A - N/A
Shares Out 87.00M
Stochastic %K 88%
Beta 0.18
Analysts Strong Sell
Price Target $13.11

Company Profile

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company's lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabet...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 206 4507
Address:
275 Shoreline Drive, Suite 500, Redwood City, United States
SocioCobb
SocioCobb Aug. 22 at 2:15 PM
$RZLT absolutely on 🔥
0 · Reply
Monty3030
Monty3030 Aug. 21 at 5:17 PM
$RZLT
0 · Reply
oaksapollo
oaksapollo Aug. 21 at 4:32 PM
$RZLT we may hit $7 today
1 · Reply
Shlobby
Shlobby Aug. 21 at 2:19 PM
Put on $NIO and $RZLT today both breaking out
0 · Reply
oaksapollo
oaksapollo Aug. 21 at 2:16 PM
$RZLT dang it's up $0.22 on 65K shares...crazy. Nobody is selling.
0 · Reply
GollumSmeagol
GollumSmeagol Aug. 20 at 8:08 PM
$IOVA $PGEN $RZLT Closed PGEN successfully at over 100% gains. RZLT humming along, hit a new 52 week high today. IOVA is down (significantly) but the 2H of this year looks promising, added today and yesterday to bring down that avg. Started a position in EWTX will DCA accordingly. Good luck all.
0 · Reply
Monty3030
Monty3030 Aug. 20 at 7:07 PM
$RZLT New 52 week high!! Lets gooooo!!!
1 · Reply
Monty3030
Monty3030 Aug. 20 at 7:04 PM
$RZLT We are about to bust through the seams!! This thing is coiling more than a rocket on a launchpad!
0 · Reply
GollumSmeagol
GollumSmeagol Aug. 20 at 6:20 PM
$RZLT loving the sustained price around $6.50 if we can maintain/rise into December, I think positive data could send us to double digits. Holding and adding. Nice add on the CCO today. Wharton grad and another Ultragenyx member after their CCO joined RZLT BOD in March. Very interesting to say the least.
0 · Reply
oaksapollo
oaksapollo Aug. 20 at 3:31 PM
$RZLT all signs pointing to no buyout in the near term. Guess we are waiting for data in December.
2 · Reply
Latest News on RZLT
Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer

Aug 20, 2025, 7:30 AM EDT - 3 days ago

Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

Jul 22, 2025, 7:30 AM EDT - 4 weeks ago

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

Jul 9, 2025, 7:30 AM EDT - 6 weeks ago

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

May 28, 2025, 8:00 AM EDT - 3 months ago

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 13, 2025, 4:05 PM EDT - 3 months ago

Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

May 5, 2025, 8:00 AM EDT - 3 months ago

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute to Participate in Upcoming Investor Conferences

May 1, 2025, 8:00 AM EDT - 4 months ago

Rezolute to Participate in Upcoming Investor Conferences

Rezolute: RZ402 Could Be A Surprise Candidate In The Making

May 1, 2025, 3:57 AM EDT - 4 months ago

Rezolute: RZ402 Could Be A Surprise Candidate In The Making

Rezolute, Inc. Announces Closing of Underwritten Offering

Apr 25, 2025, 4:30 PM EDT - 4 months ago

Rezolute, Inc. Announces Closing of Underwritten Offering

Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December

Apr 23, 2025, 3:50 PM EDT - 4 months ago

Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December

Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants

Apr 23, 2025, 8:05 AM EDT - 4 months ago

Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants

Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)

Apr 23, 2025, 8:00 AM EDT - 4 months ago

Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)

Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

Mar 26, 2025, 7:30 AM EDT - 5 months ago

Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

Rezolute: Late-Stage Study Targeting Hyperinsulinism

Feb 18, 2025, 1:30 AM EST - 6 months ago

Rezolute: Late-Stage Study Targeting Hyperinsulinism

Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Feb 12, 2025, 4:05 PM EST - 6 months ago

Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Feb 4, 2025, 8:00 AM EST - 7 months ago

Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference

Jan 31, 2025, 8:00 AM EST - 7 months ago

Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference

Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Dec 5, 2024, 8:00 AM EST - 9 months ago

Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Rezolute: Ersodetug Downstream Tech Could Ignite The Hyperinsulinism Market

Dec 3, 2024, 3:56 PM EST - 9 months ago

Rezolute: Ersodetug Downstream Tech Could Ignite The Hyperinsulinism Market

Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update

Sep 19, 2024, 4:05 PM EDT - 1 year ago

Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update

FDA Gives Green Signal To Rezolute's Genetic Disorder Treatment

Sep 9, 2024, 10:41 AM EDT - 1 year ago

FDA Gives Green Signal To Rezolute's Genetic Disorder Treatment

US FDA lifts partial clinical hold on Rezolute's blood sugar treatment

Sep 9, 2024, 7:47 AM EDT - 1 year ago

US FDA lifts partial clinical hold on Rezolute's blood sugar treatment

FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

Sep 9, 2024, 7:30 AM EDT - 1 year ago

FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Aug 5, 2024, 7:30 AM EDT - 1 year ago

Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement

Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds

Jun 24, 2024, 8:00 AM EDT - 1 year ago

Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds

Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants

Jun 13, 2024, 11:30 PM EDT - 1 year ago

Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jun 13, 2024, 4:01 PM EDT - 1 year ago

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Rezolute to Participate in the Jefferies Global Healthcare Conference

May 30, 2024, 8:00 AM EDT - 1 year ago

Rezolute to Participate in the Jefferies Global Healthcare Conference

Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

May 21, 2024, 4:05 PM EDT - 1 year ago

Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

May 15, 2024, 4:05 PM EDT - 1 year ago

Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting

Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

Mar 6, 2024, 7:30 AM EST - 1 year ago

Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

Feb 13, 2024, 4:05 PM EST - 1 year ago

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer

Jan 24, 2024, 8:00 AM EST - 1 year ago

Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer

Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Jan 23, 2024, 8:00 AM EST - 1 year ago

Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism

Dec 14, 2023, 8:00 AM EST - 1 year ago

Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism

Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)

Dec 13, 2023, 8:00 AM EST - 1 year ago

Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)

Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"

Nov 24, 2023, 11:14 AM EST - 1 year ago

Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"

Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day

Nov 17, 2023, 8:00 AM EST - 1 year ago

Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day

Rezolute Reports First Quarter Fiscal 2024 Results

Nov 13, 2023, 4:05 PM EST - 1 year ago

Rezolute Reports First Quarter Fiscal 2024 Results

Rezolute: Negative EV Opportunity Initiating A Phase 3 Ultra-Orphan Pediatric Study

Nov 9, 2023, 6:57 PM EST - 1 year ago

Rezolute: Negative EV Opportunity Initiating A Phase 3 Ultra-Orphan Pediatric Study

Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism

Rezolute Announces Further Evidence of RZ358's Efficacy in Tumor-Mediated Hyperinsulinism

Oct 11, 2023, 8:00 AM EDT - 2 years ago

Rezolute Announces Further Evidence of RZ358's Efficacy in Tumor-Mediated Hyperinsulinism

Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress

Sep 14, 2023, 4:05 PM EDT - 2 years ago

Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress

Rezolute to Participate in Upcoming Investor Conferences in September

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Rezolute to Participate in Upcoming Investor Conferences in September

Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism

Jun 27, 2023, 4:05 PM EDT - 2 years ago

Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism

Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease

Jun 1, 2023, 12:45 PM EDT - 2 years ago

Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease

OCS

Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress

May 11, 2023, 4:05 PM EDT - 2 years ago

Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress

Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema

Mar 23, 2023, 4:50 PM EDT - 2 years ago

Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema

SocioCobb
SocioCobb Aug. 22 at 2:15 PM
$RZLT absolutely on 🔥
0 · Reply
Monty3030
Monty3030 Aug. 21 at 5:17 PM
$RZLT
0 · Reply
oaksapollo
oaksapollo Aug. 21 at 4:32 PM
$RZLT we may hit $7 today
1 · Reply
Shlobby
Shlobby Aug. 21 at 2:19 PM
Put on $NIO and $RZLT today both breaking out
0 · Reply
oaksapollo
oaksapollo Aug. 21 at 2:16 PM
$RZLT dang it's up $0.22 on 65K shares...crazy. Nobody is selling.
0 · Reply
GollumSmeagol
GollumSmeagol Aug. 20 at 8:08 PM
$IOVA $PGEN $RZLT Closed PGEN successfully at over 100% gains. RZLT humming along, hit a new 52 week high today. IOVA is down (significantly) but the 2H of this year looks promising, added today and yesterday to bring down that avg. Started a position in EWTX will DCA accordingly. Good luck all.
0 · Reply
Monty3030
Monty3030 Aug. 20 at 7:07 PM
$RZLT New 52 week high!! Lets gooooo!!!
1 · Reply
Monty3030
Monty3030 Aug. 20 at 7:04 PM
$RZLT We are about to bust through the seams!! This thing is coiling more than a rocket on a launchpad!
0 · Reply
GollumSmeagol
GollumSmeagol Aug. 20 at 6:20 PM
$RZLT loving the sustained price around $6.50 if we can maintain/rise into December, I think positive data could send us to double digits. Holding and adding. Nice add on the CCO today. Wharton grad and another Ultragenyx member after their CCO joined RZLT BOD in March. Very interesting to say the least.
0 · Reply
oaksapollo
oaksapollo Aug. 20 at 3:31 PM
$RZLT all signs pointing to no buyout in the near term. Guess we are waiting for data in December.
2 · Reply
Monty3030
Monty3030 Aug. 19 at 2:35 PM
$RZLT 12.50 Option Strike has been added to all 2026 options. Great sign!
0 · Reply
oaksapollo
oaksapollo Aug. 18 at 5:53 PM
$RZLT pennies from a new 52-week high. I think we set a new one before the day is out.
1 · Reply
Monty3030
Monty3030 Aug. 15 at 8:23 PM
$RZLT Dragonfly doji has formed on the daily!! If this Russia/Ukraine deal gets legs we could have a major uptick next week.
0 · Reply
Bumsdi
Bumsdi Aug. 14 at 3:46 PM
$GLXY $RZLT $BTBT still good in the money - this shitshown is so funny to look at - just holding my shares and chilling . Always the same - shorts and institutes want to get us out - high pressure - many panic sales - chillex and lean back
0 · Reply
SocioCobb
SocioCobb Aug. 14 at 12:48 AM
$RZLT 4 month 2 banger
0 · Reply
oaksapollo
oaksapollo Aug. 13 at 7:00 PM
$RZLT 1016 $10 Jan 2026 contracts traded today alone, covering 101,600 shares. This puts open interest at 7299 (covering 729,900 shares). Buyers are paying $1.60 for a call that expires in 5 months and requires a 50% gain from here. Very bullish.
1 · Reply
Monty3030
Monty3030 Aug. 13 at 5:42 PM
$RZLT Huge Option activity today for Jan 2026 10 dollar calls. Someone just bought a 1,000 contracts at the sweep!! Get ready!!
2 · Reply
oaksapollo
oaksapollo Aug. 13 at 3:54 PM
$RZLT new 52 week high
2 · Reply
SannieVerraderlijk
SannieVerraderlijk Aug. 13 at 11:21 AM
Small bio shuffle. Will take a small 8% loss here on $DAWN underwhelming launch. Moving it to more successful launches (TARS, $SNDX) and promising pipelines ($BHVN, ABVX, AKRO). Trailing stop loss for $RZLT (+63%) to buy back on any dip.
0 · Reply
GollumSmeagol
GollumSmeagol Aug. 12 at 2:17 PM
$RZLT Excited for data in December, holding and adding on dips
0 · Reply
oaksapollo
oaksapollo Aug. 11 at 3:09 PM
$RZLT even when the stock appears calm, nothing going on, the smart money is accumulating Jan 2026 calls. $10 strike seems to be the favorite.
0 · Reply
Monty3030
Monty3030 Aug. 6 at 9:02 PM
$RZLT Fidelity just doubled their position in the latest sec filing for RZLT! They are now a 15% owner! Get ready!
1 · Reply